Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Currency in USD	2025
Operating Income	-1.18 Billion
Income Before Tax	-1.13 Billion
Income Tax Expense	0.00
Net Income	-1.13 Billion
Eps	-5.95
Epsdiluted	-5.95
Weighted Average Shs Out	190.13 Million
Weighted Average Shs Out Dil	190.13 Million
Research And Development Expenses	987.33 Million
Selling General And Administrative Expenses	N/A
Depreciation And Amortization	7.78 Million
Interest Expense	24.23 Million
Interest Income	90.69 Million
Net Interest Income	66.46 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	N/A
Ebitda	-1.17 Billion
Source	edgar
Ebit	-1.11 Billion

Revolution Medicines, Inc. Annual Reports (10-K)